MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.24
-0.02
-0.28%
After Hours: 7.28 +0.04 +0.55% 18:46 09/17 EDT
OPEN
7.24
PREV CLOSE
7.26
HIGH
7.51
LOW
7.17
VOLUME
346.48K
TURNOVER
--
52 WEEK HIGH
27.51
52 WEEK LOW
6.30
MARKET CAP
81.35M
P/E (TTM)
-1.6515
1D
5D
1M
3M
1Y
5Y
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall Healthc...
GlobeNewswire · 1d ago
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
-Study found that approximately 30% of patients who are dependent on parenteral nutrition have cholestasis- -Results support significant unmet medical need in patients dependent on parenteral nutrition who have intestinal failure associated liver disease- ...
GlobeNewswire · 5d ago
A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 09/09 14:31
Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management...
GlobeNewswire · 09/07 12:00
--BofA Securities Starts Protara Therapeutics at Buy With $15 Price Target
MT Newswires · 08/30 07:47
60 Biggest Movers From Yesterday
Gainers
Benzinga · 08/25 08:50
Triple-S Management, Bio-Path leads healthcare gainers; Theravance Biopharma, Vivos Therapeutics among major losers
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) -31%, Vivos...
Seekingalpha · 08/24 15:10
Protara Therapeutics-Sponsored Study Titled 'Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition (THRIVE-1)' Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05011370
Benzinga · 08/18 13:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TARA. Analyze the recent business situations of Protara Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TARA stock price target is 40.00 with a high estimate of 50.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 10.40M
% Owned: 92.53%
Shares Outstanding: 11.24M
TypeInstitutionsShares
Increased
8
309.90K
New
9
264.58K
Decreased
18
463.04K
Sold Out
17
1.53M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Luke Beshar
President/Chief Executive Officer/Director
Jesse Shefferman
Chief Financial Officer
Blaine Davis
Chief Operating Officer/Chief Scientific Officer
Jacqueline Zummo
Vice President/IR Contact Officer
Justine O'Malley
Other
Martin Olivo
Director
Jane Huang
Independent Director
Barry Flannelly
Independent Director
Roger Garceau
Independent Director
Richard Levy
Independent Director
Gregory Sargen
Independent Director
Cynthia Smith
Independent Director
Michael Solomon
No Data
About TARA
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.

Webull offers kinds of Protara Therapeutics Inc stock information, including NASDAQ:TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.